VJHemOnc Podcast
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
Jul 1, 2024
Experts Toby Eyre and Lydia Scarfò discuss the latest updates in CLL treatment, including BTK and BCL2 inhibitor combinations, BTK degraders, and the role of epcoritamab in Richter’s transformation. They explore the trade-off between toxicity and efficacy, potential sequencing strategies, and promising results in heavily pretreated CLL patients, offering insights on future treatments and clinical trials.
12:10
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Combinations of BTK and BCL2 inhibitors show high efficacy in CLL, particularly in high-risk patients with genetic aberrations.
- BTK degraders exhibit promising response rates in heavily pre-treated CLL patients, suggesting a new avenue for treatment.
Deep dives
Combinations of BTK and BCL2 Inhibitors in CLL
Discussions on the efficacy of combinations of BTK and BCL2 inhibitors in chronic lymphocytic leukemia (CLL) highlighted data from the Sequoia trial, showing high efficacy in a high-risk population with 17p deletion or TP53 aberrations. The combination of Serontoclax and Xanabarutinib in relapsed CLL patients demonstrated excellent response rates and promising tolerability, moving into a randomized clinical trial for further validation.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
